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Despite the rapid expansion in recent years of databases reporting either benign or pathogenic genetic
variations, the interpretation of novelmissense variants remains challenging, particularly for clinical or
genetic testing laboratories where functional analysis is often unfeasible. Previous studies have shown
that thermodynamic analysis of protein structure in silico can discriminate between groups of benign
and pathogenic missense variants. However, although structures exist for many human disease‒
associated proteins, such analysis remains largely unexploited in clinical laboratories. Here, we an-
alyzed the predicted effect of 338 known missense variants on the structure of menin, the MEN1 gene
product. Results provided strong discrimination between pathogenic and benign variants, with a
threshold of .4 kcal/mol for the predicted change in stability, providing a strong indicator of patho-
genicity. Subsequent analysis of seven novel missense variants identified during clinical testing of
patients with MEN1 showed that all seven were predicted to destabilize menin by .4 kcal/mol.
We conclude that structural analysis provides a useful tool in understanding the effect of missense
variants inMEN1 and that integration of proteomic with genomic data could potentially contribute to
the classification of novel variants in this disease.
This article has been published under the terms of the Creative Commons Attribution License (CC
BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricteduse, distribution, and
reproduction in any medium, provided the original author and source are credited. Copyright for
this article is retained by the author(s).
Freeform/KeyWords:multiple endocrine neoplasia type 1, protein structure, missense variant
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The rapid expansion in recent years of genomic data from both patient and control groups has
vastly improved the quantity and quality of information available to clinicians who are
attempting to classify novel genetic variants. Although interpretation of likely loss-of-
function variants such as stop-gain or frameshift variants is often straightforward, the
same is not true of missense variants, for which the effect of an amino acid substitution is
likely to be specific to its context in the protein of interest. Moreover, such variants are often
rare or unique and thus must be interpreted on a case by case basis.
Numerous methods have been developed for predicting the phenotypic effect of missense
variants. As has been comprehensively reviewed elsewhere [1], these methods rely on
analysis of DNA and protein conservation, protein structure-based analysis, or a combination
of the two. In the latter, widely used tools such as PolyPhen may incorporate information on
the nature of the amino acid change itself (e.g., Grantham distance between native and
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variant amino acids, changes in polarity or charge), effects on predicted secondary structure,
and where available, data derived from the structural context, such as changes in hydrogen
bonding or atomic crowding. However, such data are used in a qualitative, rule-basedmanner
in the final prediction [1], and the tools most widely used in the clinical setting do not
specifically address the quantitative effects of missense variants on protein stability. Nev-
ertheless, these effects can be calculated when there is an experimental or modeled three-
dimensional structure for the protein of interest; FoldX [2], Rosetta [3, 4], and other
computational methods have been widely used by structural biologists to investigate the
effects of missense variants on protein folding and stability [5, 6]. Despite this, few studies
have addressed whether there is a direct clinical application of such an approach (i.e.,
whether pathogenic and benign variants can be distinguished on the basis of their predicted
effects on thermodynamic stability).
The potential utility of protein stability data in the analysis of missense variants was
recently demonstrated in studies of the Lynch syndrome protein MSH2 [7] and in phenyl-
alanine hydroxylase (PAH) [8], in which pathogenic variants result in phenylketonuria. Both
of these studies combined in silico analysis with extensive functional analysis of a number of
MSH2 and PAH variants; however, resources for the latter are unlikely to be routinely
available in clinical genetics laboratories. We therefore asked whether in silico analysis,
based predominantly on the predicted effects of missense variants on protein stability, can
help discriminate between pathogenic and benign variations in the context of clinical testing
of the MEN1 gene.
Pathogenic variants in theMEN1 gene causemultiple endocrine neoplasia type 1 (MEN1), an
autosomal dominant disorder in which patients develop neoplastic lesions in various endocrine
tissues, principally the parathyroids, pituitary, and pancreas [9]. Pathogenic variants may be
either inherited or acquired; in both cases, however, development of disease requires loss of
heterozygosity consistent with a role for menin, theMEN1 gene product, as a tumor suppressor.
The biological activity of menin is not fully understood, but it is known to bind to and inhibit the
activity of JunD [10], a component of the proliferation-associated transcription factor AP-1. Loss
of menin activity is presumed to result in deregulated activity of AP-1, leading to increased cell
proliferation andultimately neoplasia.Menin also regulates gene expression via interactionwith
the histone methyltransferase KMT2A (MLL1) and forms an essential component of the MLL
complex,which upregulates expression from target genes including those of theHOX cluster [11].
Menin may also play a role in DNA damage repair via an interaction with FANCD2, and loss of
activity has been shown to result in increased sensitivity toDNAdamage [12]. Finally,menin has
been shown to repress telomerase activity, and depletion ofmenin in human fibroblasts results in
their immortalization [13]. Thus, loss of menin activity could lead to neoplasia and tumor
formation via a number of potential pathways.
The most common presenting feature in patients with MEN1 is hyperparathyroidism,
which occurs in ;95% of these patients as a result of tumors of the parathyroid gland;
however, tumors are also frequently observed in the pancreatic islets (40% to 70% of patients)
and pituitary (30% to 40% of patients) [14]. Patients may also develop tumors of the adrenal
cortex, carcinoid tumors, and nonendocrine tumors, including lipomas, angiofibromas, col-
lagenomas, andmeningiomas [15], resulting in a range of clinical symptoms thatmay overlap
with those of diseases of different genetic etiology [16–18]. This overlap presents one of the
key problems in assessing genetic variants in cases of MEN1. Although a large number of
pathogenic variants have been reported inMEN1, genetic testing continues to uncover novel
missense substitutions that require assessment of their potential pathogenicity. A further
confounding issue is the often later onset of disease, with reported age-related penetrance of
10% to 43% at 20 years and 81% to 94% by 50 years [14, 19], which may lead to apparent
nonsegregation of a variant with disease within a family pedigree.
The identification of a genetic etiology has important implications for the patient and for
his or her family members. With the exception of pituitary neuroendocrine tumors, MEN1-
associated tumors are usually multiple; treatment is therefore challenging, requiring a
multidisciplinary team of experts to reducemorbidity andmortality [20]. The identification of
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the familial disease-causing variant enables the identification of carriers when they are still
asymptomatic. Clinical surveillance in these individuals allows early recognition of the
clinical manifestations and therapeutic intervention. For example, primary hyperparathy-
roidism often remains asymptomatic in many patients, but prolonged hypercalcemia usually
results in bone loss and/or nephrocalcinosis [21].
Approximately 20% of the variants identified in theMEN1 gene are missense variants [22].
The standards and guidelines published by the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology describe a framework for the classi-
fication of sequence variants [23]. Adjustments to this framework have been proposed for the
interpretation ofMEN1missense variants [24]. However both agree that variants of uncertain
significance should not be used to guide the clinical management of patients. This could lead to
an underdiagnosis of MEN1 and a lost opportunity for screening of at-risk relatives. For these
reasons, methods that assist in the classification of variants inMEN1 are of clinical value. The
availability of a number of experimental structures for menin, theMEN1 gene product, raises
the possibility that structural analysis may provide such clinical utility.
We report here that thermodynamic analysis of MEN1 variants in silico provided a very
strong positive predictive value (PPV) for pathogenicity, thereby helping to assess the effect of
novel missense variants on protein function and potentially allowing the use of such analysis
in variant classification. We also discuss briefly the wider application of this approach to
other diseases.
1. Materials and Methods
A. Variant Groups, Transcripts, and Numbering
Lists of previously reported inherited missense single nucleotide variants in MEN1 were
downloaded from the Human Gene Mutation Database, Professional version (HGMD Pro)
[25]; the Genome Aggregation Database (gnomAD) [26], and the Sydney Genomics Collab-
orative Database (SGCD) [27]. For the purposes of this analysis, variants were divided into
groups as follows: pathogenic: “disease mutation” (DM) class variants reported in the HGMD
Pro but not in the gnomAD or SGCD (n 5 162); benign: variants reported in the gnomAD or
SGCD but not as DM class in the HGMD Pro (n 5 206); and uncertain: variants reported as
DM in theHGMDPro and present in the gnomAD and/or SGCD (n5 14). Different nucleotide
substitutions resulting in the same coding change were regarded as a single missense
substitution. In addition to these previously reported variants, analysis was performed on
seven novel missense variants: H46P, A164P, L175P, A345P, I360F, F364S, and G419D (see
Table 1 for details). These variants were identified in our laboratory as part of the National
Health Service (England) Genetic Testing Service for rare inherited diseases. The patients
tested fulfilled the criteria for a clinical diagnosis of MEN1 [14], presenting with at least two
of the three main MEN1-associated endocrine lesions or one typical MEN1-associated tumor
and a first-degree relative with MEN1 or a MEN1-associated lesion at a young age. For
patients with a family history, the relevant variants (H46P, A164P, I360F, and F364S) were
all shown to cosegregate with disease in the family. Informed consent for genetic testing was
obtained from all subjects.
There is one major isoform (610 amino acids) and oneminor isoform (615 amino acids) of
menin in the sequence databases. The longer minor isoform could have originated with
use of an alternative splice donor site in exon 1, such that the longer isoform contains five
residues inserted at the end of exon 1 (at amino acid 148) that lead to a total 615‒amino
acid coding region. Although the gnomAD and SGCD variants are annotated according to
the 615-residue isoform encoded by transcripts NM_130803/ENST00000337652, the
HGMD Pro and structural databases use the 610-residue isoform encoded by NM_130799/
ENST00000312049 as the default. All numbering in this manuscript refers to the 610-
residue form of menin, and variants from the gnomAD and SGCD have been reannotated
accordingly.
2260 | Journal of the Endocrine Society | doi: 10.1210/js.2019-00260
T
a
b
le
1.
D
et
a
il
s
o
f
S
ev
en
N
o
v
el
M
is
se
n
se
V
a
ri
a
n
ts
in
M
E
N
1
V
a
ri
a
n
t
N
o
.
1
2
3
4
5
6
7
H
G
V
S
c.
n
ot
at
io
n
c.
13
7A
.
C
c.
49
0G
.
C
c.
52
4T
.
C
c.
10
33
G
.
C
c.
10
78
A
.
T
c.
10
91
T
.
C
c.
12
56
G
.
A
H
G
V
S
p.
n
ot
at
io
n
p.
(H
is
46
P
ro
)
p.
(A
la
16
4P
ro
)
p.
(L
eu
17
5P
ro
)
p.
(A
la
34
5P
ro
)
p.
(I
le
36
0P
h
e)
p.
(P
h
e3
64
S
er
)
p.
(G
ly
41
9A
sp
)
G
en
om
ic
va
ri
an
t
(G
R
C
h
37
/h
g1
9)
ch
r1
1:
64
57
74
45
T
.
G
ch
r1
1:
64
57
55
27
C
.
G
ch
r1
1:
64
57
54
93
A
.
G
ch
r1
1:
64
57
37
20
C
.
G
ch
r1
1:
64
57
32
14
T
.
A
ch
r1
1:
64
57
32
01
A
.
G
ch
r1
1:
64
57
26
00
C
.
T
R
ep
or
te
d
in
gn
om
A
D
?
N
o
N
o
N
o
N
o
N
o
N
o
N
o
S
IF
T
pr
ed
ic
ti
on
D
am
ag
in
g
D
am
ag
in
g
D
am
ag
in
g
D
am
ag
in
g
D
am
ag
in
g
D
am
ag
in
g
D
am
ag
in
g
P
R
O
V
E
A
N
pr
ed
ic
ti
on
D
el
et
er
io
u
s
D
el
et
er
io
u
s
D
el
et
er
io
u
s
D
el
et
er
io
u
s
D
el
et
er
io
u
s
D
el
et
er
io
u
s
D
el
et
er
io
u
s
P
ol
yP
h
en
pr
ed
ic
ti
on
P
ro
ba
bl
y
da
m
ag
in
g
P
ro
ba
bl
y
da
m
ag
in
g
P
ro
ba
bl
y
da
m
ag
in
g
P
ro
ba
bl
y
da
m
ag
in
g
P
ro
ba
bl
y
da
m
ag
in
g
P
ro
ba
bl
y
da
m
ag
in
g
P
ro
ba
bl
y
da
m
ag
in
g
R
E
V
E
L
sc
or
e
0.
89
4
0.
92
5
0.
96
5
0.
90
9
0.
88
3
0.
94
5
0.
91
2
A
ll
va
ri
an
ts
re
fe
r
to
M
E
N
1
tr
an
sc
ri
pt
N
M
_1
30
79
9.
2,
pr
ot
ei
n
N
P
_5
70
71
1.
1
(6
10
‒
am
in
o
ac
id
is
of
or
m
).
A
bb
re
vi
at
io
n
:
H
G
V
S
,
H
u
m
an
G
en
om
e
V
ar
ia
ti
on
S
oc
ie
ty
.
doi: 10.1210/js.2019-00260 | Journal of the Endocrine Society | 2261
B. Protein Structures
Structures of human menin were downloaded as Protein Data Bank (PDB) files from the
worldwide PDB [28]; a full list of the 29 crystal structures, containing 31 discrete menin
chains, used in this analysis is shown in Table 2. Any nonnative amino acids (e.g., affinity
purification tags) in these structures were removed from PDB files before further analysis.
Table 2. MEN1 Crystal Structures Used in FoldX Analysis
PDB
ID Title Resolution (A˚)
Release
Date
Menin
Chain(s)
Used for
RSA
Analysis? Reference
3u84 Crystal structure of human menin 2.50 15/2/2012 A, B Yes (chain A) 29
3u85 Crystal structure of humanmenin in
complex with MLL1 (KMT2A)
3.00 15/2/2012 A Yes
3u86 Crystal structure of humanmenin in
complex with JunD
2.84 15/2/2012 A
3u88 Crystal structure of humanmenin in
complex with MLL1 (KMT2A) and
LEDGF (PSIP)
3.00 15/2/2012 A, B Yes (chain B)
4gpq Structural insights into inhibition of
the bivalent menin-MLL
interaction by small molecules in
leukemia
1.46 19/9/2012 A 30
4gq3 Human menin with bound inhibitor
MI-2
1.56 19/9/2012 A
4gq4 Human menin with bound inhibitor
MI-2-2
1.27 19/9/2012 A
4gq6 Humanmenin in complex with MLL
(KMT2A) peptide
1.55 19/9/2012 A
4i80 Crystal structure of humanmenin in
complex with a high-affinity
macrocyclic peptidomimetic
3.10 6/3/2013 A Yes 31
4og3 Human menin with bound inhibitor
MIV-3R
2.01 5/3/2014 A 32
4og4 Human menin with bound inhibitor
MIV-3S
1.45 5/3/2014 A
4og5 Human menin with bound inhibitor
MIV-5
1.63 5/3/2014 A
4og6 Human menin with bound inhibitor
MIV-4
1.49 5/3/2014 A
4og7 Human menin with bound inhibitor
MIV-7
2.08 5/3/2014 A
4og8 Human menin with bound inhibitor
MIV-6R
1.53 5/3/2014 A
4x5y Menin in complex with MI-503 1.59 15/4/2015 A 33
4x5z Menin in complex with MI-136 1.86 15/4/2015 A
5db0 Menin in complex with MI-352 1.50 30/3/2016 A 34
5db1 Menin in complex with MI-336 1.86 30/3/2016 A
5db2 Menin in complex with MI-389 1.54 30/3/2016 A
5db3 Menin in complex with MI-574 1.71 30/3/2016 A
5dd9 Menin in complex with MI-326 1.62 9/9/2015 A 35
5dda Menin in complex with MI-333 1.83 9/9/2015 A Yes
5ddb Menin in complex with MI-319 1.54 9/9/2015 A
5ddc Menin in complex with MI-2-3 1.62 6/7/2016 A
5ddd Menin in complex with MI-836 2.14 9/9/2015 A
5dde Menin in complex with MI-859 1.78 9/9/2015 A
5ddf Menin in complex with MI-273 1.66 9/9/2015 A Yes
6b41 Menin bound to M-525 2.61 24/1/2018 A Yes 36
A total of 29 PDB structures containing 31 menin chains were used for thermodynamic analysis using FoldX; seven
representative structures were also used for relative solvent accessibility (RSA) analysis.
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C. In Silico Mutagenesis and Thermodynamic Analysis
Before in silicomutagenesis, sidechain repair and energyminimizationwere performed on all
31 menin chains in isolation, using the RepairPDB function of the FoldX modeling suite [2],
version 4. The FoldX BuildModel function was then used to introduce individual sub-
stitutions into each of the repaired PDB structures. Of the 389 unique missense variants, 338
were covered by at least one PDB structure (pathogenic, n5 161; benign, n5 161; uncertain,
n 5 9; novel, n 5 7). For each substitution, FoldX reported a change in free energy (DDG)
resulting from the substitution; from this, an average DDG value was calculated for each
variant across all structures containing the relevant position. In total, all 31 structures were
used for 308 of 338 variants (mean for all variants 5 29 structures), whereas analysis was
possible using only a single structure for seven variants because of differences in coverage of
individual PDB files. A full list of variants, the number of PDB structures analyzed for each,
and average DDG values for each variant have been published online [37]. All structures were
visualized in PyMOL [38].
D. Calculation of Solvent Accessibility
The absolute area accessible to solvent was calculated on a residue-by-residue basis for seven
representative structures of menin using Define Secondary Structure of Proteins algorithm
[39, 40] version 3.0.0 [41]. After an average area accessible to solvent value was calculated for
each residue, relative solvent accessibility (RSA) was derived using the theoretical scale
described by Tien et al. [42]. A list of structures used for DSSP analysis is included in Table 2.
2. Results
A. Pathogenic Variants in MEN1 Are Predicted to Be More Destabilizing Than
Benign Variants
More than 30 crystal structures were previously reported for menin [Fig. 1(a)]; most of these
contain the protein in isolation or bound to a small (drug) ligand, whereas others showmenin
in complex with peptides from JunD, KMT2A, or PSIP [Fig. 1(b); Table 2]. Although all
structures have been derived from expression of full-length (or near full‒length) menin, a
number of regions remain unresolved in crystal structures. These regions predominantly lie
in the C-terminal of the protein and correspond to stretches of predicted intrinsic disorder
[43] in the protein [Fig. 1(c) and 1(d)], presumably resulting in high mobility within crystals.
Interestingly, although these regions contain a similar distribution of benign variants as seen
in the protein as a whole, inherited pathogenic variants are rare in regions of predicted
disorder in menin [Fig. 1(d)]; however, we cannot rule out the possibility that the lack of
pathogenic variants in these regions is due to reporting bias toward variants that lie close to
those already known. Furthermore, recurrent missense variants have been observed in
disordered regions of menin in the COSMIC database of somatic mutations in cancer [44], of
which three (R479W, R485Q, and P540R) have not been reported in the gnomAD. It is
therefore possible that missense variants in disordered regions play a role in pathogenicity,
particularly when they arise as somatic mutations. With respect to inherited pathogenic
variants, however, their distribution almost entirely within ordered regions means that the
vast majority (161 of 162) are covered by one or more PDB entries and are thus amenable to
structural analysis.
The overall structure of menin is highly comparable to that within all reported PDB
structures (alignment to PDB 6b41 yields an average root-mean-square deviation of 0.65 A˚;
range, 0.55 to 1.10 A˚). Moreover, there is no significant effect of ligand binding on menin
structure (Fig. 2). Because different PDB files contain slightly different numbers of amino
acids but there are no obvious structural outliers, all available structures were used for
thermodynamic analysis of missense variants in silico using FoldX.
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Benign and pathogenic variant groups were highly distinguishable by their predicted
effect on thermodynamic stability, as represented by average DDG value calculated across
all structures. Variants resulting in DDG .3 kcal/mol are generally regarded as strongly
Figure 1. Structure and disorder in menin. (a) The structure of menin, as represented by
PDB entry 3u88 chain A. The protein surface is colored from blue, N-terminal, to red,
C-terminal; the position of the binding pocket for JunD and KMT2A is indicated (arrow).
Magenta numbered residues indicate positions flanking disordered loops, which are not
resolved in the crystal structure. (b) Menin (gray) in complex with KMT2A (yellow) and PSIP
(green), as determined in PDB 3u88; note that although one end of KMT2A occupies the
binding pocket, interaction with PSIP and other regions of KMT2A extends over a wider
region of the menin surface. (c) Probability of intrinsic disorder in menin, as calculated by
the MetaDisorder predictor, plotted against amino acid position. Extended regions of
probability .0.5 are considered disordered. (d) Coverage of menin residues in the 31 PDB
structures used in this analysis, aligned against amino acid position as in part (c). The top
line shows coverage in PDB 3u88A, colored as in (a); numbering indicates residues flanking
unstructured regions missing from the crystal structure. Below this, black horizontal lines
show coverage for the 30 remaining PDB structures, whereas positions of benign and
pathogenic variants are indicated by blue or red triangles, respectively. Note that regions of
predicted intrinsic disorder are absent from the majority of, if not all, crystal structures,
consistent with greater mobility of these residues within the crystal, and that few pathogenic
variants have been reported in these regions.
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destabilizing [45]. The average DDG value for all pathogenic variants was 5.06 kcal/mol (SD,
4.25 kcal/mol), with 108 of 161 of these (67.1%) predicted to be strongly destabilizing (DDG. 3
kcal/mol). In contrast, the average DDG value for putatively benign (gnomAD and SGCD)
variants was 1.13 kcal/mol (SD, 1.46 kcal/mol), with only 17 of 161 (10.6%) having an effect in
excess of 3 kcal/mol [Fig. 3(a)]. Of note, all seven novel missense variants were also predicted
to be strongly destabilizing (average DDG, 7.67 kcal/mol; SD, 3.14 kcal/mol; range, 4.81 to
13.16 kcal/mol). Analysis of DDG values for individual PDB structures showed a similar
separation of putative benign and pathogenic variant groups, with the vast majority of
variants falling into a similar range for all structures [Fig. 3(b)].
We further compared the effect at multiallelic sites where different benign and pathogenic
missense variants occur at the same position. Analysis of 27 benign and 23 pathogenic
variants co-occurring at 22 residues again showed that the difference between the two groups
was highly significant (P 5 0.0002) and that, as a group, pathogenic missense changes were
more strongly destabilizing than benign ones at the same position (average DDG value by
group 5 6.81 and 2.18 kcal/mol, respectively) [Fig. 3(c)]. Therefore, because both pathogenic
and benign variations can occur at the same site withinmenin, it is important to consider both
the position and nature of the amino acid change; these data suggest that DDG value may be
useful in assessing the effect of novel variants at multiallelic sites.
If variants that destabilize menin structure do indeed have a greater tendency to be
pathogenic, it may be expected that the variants most frequently observed in the general
population have the least destabilizing effect. This appears to be the case, as variants
with the highest population frequency had average predicted DDG values in the range
Figure 2. Alignment of menin structures. (a) The a carbon atoms of the 31 menin structures
used in this study were aligned to that of PDB 6b41; each chain is shown in ribbon format,
colored by PDB and chain identifier. The position of the JunD/KMT2A binding pocket is
indicated. The short helix visible at the top right of the rotated figure corresponds to
residues 596‒608 at the extreme C-terminal of menin, which were resolved only in PDB 3u84
chain A. (b) As in (a), but superimposed with the structures of MLL (blue) and PSIP (gray)
from PDB 3u88.
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of 21 to 11 (Fig. 4); because the error in FoldX calculations is approximately 60.8 kcal/
mol [2], this suggests little or no effect of these variants on protein stability. Of note, those
variants—which have also been observed in a healthy aging population as represented by
the SGCD cohort (median age, 80 to 85 years) and are therefore most likely to be truly
benign—all occur within this range of DDG values. This group includes the only com-
monly occurring missense MEN1 variant, R171Q, which has an average DDG value of
Figure 3. Pathogenic variants are predicted to destabilize menin structure. (a) In silico
mutagenesis and thermodynamic analysis for menin variants. For each variant, the change in
thermodynamic stability, DDG, was calculated from all structures which contained the relevant
residue and an average value calculated; average values for each variant were then plotted by
variant group. Black circles and vertical lines within each data area represent median and upper
and lower quartiles, respectively. Numbers above the data points show P values (Student two-
tailed t test) between groups as indicated. (b) DDG values for benign (blue) and pathogenic (red)
variant groups were calculated for 31 individual PDB structures as shown on the x-axis. (c)
Average DDG values for benign and pathogenic variants occurring at the same amino acid
position (residues with one benign and one pathogenic variant, n 5 16; residues with two benign
and one pathogenic variant, n 5 5; residues with one benign and two pathogenic variants, n 5 1).
Colored boxes show the range between the upper and lower quartiles, and horizontal lines within
each data box show median values; data points are shown for outliers only. The difference in the
average DDG value between groups was highly significant (P 5 0.0002).
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0.15 kcal/mol. Conversely, we noted that some variants reported in the gnomAD have
DDG values .4 kcal/mol; in fact, two of these nine variants (S38P and D315Y) have also
been reported as disease causing in the HGMD Pro. As the symptoms of MEN1 often
appear only in later life, it is not unexpected that some potentially pathogenic variants
will be observed in the gnomAD database.
B. Most Pathogenic Variants Are Buried in the Menin Structure
To examinewhether there are differences in the spatial distribution of benign and pathogenic
variants, we calculated the RSA of wild-type residues at all positions of missense sub-
stitutions [37]. This showed that although positions of benign variants are distributed
throughout the volume of the protein, 86.3% of pathogenic variants occur in solvent-
inaccessible (i.e., buried) regions of RSA ,0.2 [Fig. 5(a)]. Of note, this was also true for
the seven novel variants, six of which had an RSA value ,0.02. Plotting RSA against DDG
showed that variants at buried positions were also likely to be themost strongly destabilizing
to protein structure [Fig. 5(b)]. Nevertheless, we observed that a significant number of
pathogenic variants exhibited both accessibility to solvent (RSA . 0.2) and relatively low
DDG. Mapping the positions of solvent-accessible variants onto the surface of menin showed
that, as for distribution throughout the internal volume of the protein, benign variants
tended to be distributed across the surface. In contrast, pathogenic variants appeared to occur
in clusters, one of which corresponded to binding surfaces for JunD, KMT2A, and PSIP [Fig.
5(c) and 5(d)], whereas another occurred on the menin surface opposite the JunD binding
pocket. It is therefore possible that the latter region represents the site of an as-yet unchar-
acterized functional interaction of menin. As described previously, six of seven novel missense
variants occurred at positions that were buried in the interior of the protein, whereas the only
solvent-accessible variant, H46P, occurred at the interface with KMT2A and presumably acts to
impair this interaction [Fig. 5(e)].
To further investigate the effects of protein interactions on the thermodynamic effects
of MEN1 variants, we compared DDG values for variants in PDB structure 3u88 (menin
complexed with KMT2A and PSIP peptides) by analysis of both menin chains in isola-
tion (chains A, B) and those complexed to KMT2A and PSIP. As expected, regions of de-
creased solvent accessibility in the complexes aligned with residues annotated as forming
protein-protein contacts (Fig. 6). However, the presence of bound peptides had little effect
on DDG values of benign variants, indicating that these have a neutral effect on protein
Figure 4. Population frequency of MEN1 variants. The frequency of benign and uncertain
missense variants in the gnomAD database were plotted against DDG value. Blue fill:
variants occurred in the gnomAD database only; yellow fill: variants reported in the gnomAD
and SGCD databases; gray fill: variants reported in both gnomAD and HGMD Pro (DM
class) databases. In cases where different nucleotide substitutions give rise to the same
amino acid change, frequency is shown as a total for all variant alleles.
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binding. Conversely, protein binding had a large effect on DDG values of a number of
pathogenic variants; again, these predominantly occurred at or close to protein in-
terfaces, indicating that these variants are likely to have a direct effect on ligand binding
by menin.
Figure 5. Molecular distribution of pathogenic and benign variants. (a) Relative
solvent accessibility was calculated for each variant group. Black circles and vertical
lines within each data area represent median and upper and lower quartiles,
respectively. Numbers above data points show P values (Student two-tailed t test)
between groups as indicated. (b) Buried pathogenic variants are predicted to be the
most destabilizing to menin structure. Points indicate pathogenic (red), benign (dark
blue fill), uncertain (gray fill) or novel (light blue fill) variants, respectively. Note that
six of the seven novel missense variants reported here are deeply buried within the
protein (RSA , 0.02), whereas only novel variant H46P is solvent accessible. (c and d)
Surface distribution of solvent-accessible variants. The surface of menin (gray), either
(c) alone or (d) in complex with KMT2A (yellow) and PSIP (green), shows all variants
with RSA .0.2: blue, benign; red, pathogenic; purple coloring shows positions at
which different pathogenic and benign variants were observed; the novel H46P
variant is colored cyan. The broken yellow ovals indicate a cluster of pathogenic
variants that may constitute an as-yet unidentified interface for protein-protein
interactions. (e) Menin is shown as a gray ribbon; novel missense variants are colored
cyan with sidechains displayed in stick format. KMT2A and PSIP are shown as in (d).
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C. Destabilizing Variants Reduce Levels of Functional Menin Protein
Previous reports on the effects of missense variants on levels of functional menin within the
cell showed that pathogenic variants have a tendency to increase protein turnover and/or
reduce the steady-state level of protein, whereas benign variants tend to have no such effect
[46, 47]. We correlated the previously reported effects of variants on levels of steady-state
protein with average DDG values and observed that variants that were predicted to be
strongly destabilizing in silico (DDG . 3 kcal/mol) exhibited significantly lower levels of
steady-state protein in cell-based assays (P5 0.0001) (Fig. 7), consistent with the hypothesis
that variants with high DDG values reduce the biological activity of menin.
D. Can DDG Value Be Used as an Aid to Variant Classification?
To evaluate the clinical validity of DDG values, we performed receiver operating charac-
teristic curve analysis for the groups of benign and pathogenic variants and compared the
results with the outputs from a number of commonly used phenotypic predictions tools: SIFT
[48], PolyPhen [49], and REVEL [50]. All methods yielded areas under the curve of 0.819 to
0.864, indicating that all have clinical validity [Fig. 8(a)]. However DDG analysis resulted in
the highest specificity but lowest sensitivity. DDG values.3 kcal/mol are generally regarded
as being strongly destabilizing toward protein structure [45]. Taking this as a threshold for
variant classification gave a sensitivity and a specificity of 67.1% and 89.4%, respectively
(PPV, 86.4%), whereas setting a more conservative threshold of $4 kcal/mol increased the
specificity to 95.0%, though with a concomitant loss of sensitivity (54.0%; PPV, 90.6%). A
Figure 6. Effect of protein-protein interaction on DDG. Analysis of solvent accessibility and
thermodynamic effect of variants was performed on PDB 3u88 (menin:KMT2A:PSIP
complex), both on menin chains in isolation (chains A, B) and as part of the complex. The
upper graph shows the average difference in solvent accessibility by position in the
complexed and isolated menin chains, respectively [DRSA 5 RSA (complex) 2 RSA
(isolated)]. The lower graph shows the equivalent difference in average DDG value at each
position (i.e., DDDG). Data points are labeled for variants for which DDDG 3 kcal/mol (red,
pathogenic; dark blue, benign). Background shading indicates positions of menin residues
forming contacts with KMT2A (yellow) or PSIP (green) in PDB 3u88.
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marginal increase in PPV could be obtained by combining DDG thresholds with a cutoff in the
REVEL score of 0.7, which has been reported to exclude 95% of false-positive calls [51],
yielding PPVs of 87.7% at DDG$3 kcal/mol and 91.5% at DDG$4 kcal/mol. Of note, all seven
novel missense variants reported here cluster within the upper right quadrant [Fig. 8(b)],
consistent with a severe effect on protein stability and suggesting that DDG values can
potentially be used to provide evidence toward variant classification in MEN1.
3. Discussion
Previous work has shown that predicted thermodynamic destabilization of protein structure,
asmeasured byDDG values calculated by FoldX, can be used as a predictor of pathogenicity in
MSH2 and PAH variants [7, 8]. Our data indicate that the same is true for variants inMEN1
and that a high predicted DDG value is a strong positive predictor for pathogenicity. A
threshold value of DDG .3 kcal/mol, which is generally regarded as strongly destabilizing,
yielded a specificity of 89.4% for classification of menin variants, rising to 95.0% for a more
conservative threshold of 4 kcal/mol. By contrast, using a proposed threshold of 0.7 for the
phenotypic meta-prediction tool REVEL yielded a specificity of only 53%. Although MEN1
has a high degree of penetrance, with more than 95% of individuals with pathogenic variants
expected to develop symptoms by the sixth decade of life [9], there appears to be no correlation
between MEN1 variants and clinical manifestations, with interfamilial and intrafamilial
variations observed [22]. Therefore, the identification of likely pathogenic variants has
important implications for patient surveillance and genetic testing of family members. For
example, analysis of a large cohort of Florentine patients showed that age at genetic diagnosis
Figure 7. Predicted thermodynamic stability correlated with observed expression. (a)
Steady-state expression levels have been reported for a number of menin variants; relative
expression level data were sorted into two groups according to DDG value as calculated in
this study [neutral or weakly destabilizing: DDG , 3 kcal/mol (n 5 14); strongly
destabilizing: .3 kcal/mol (n 5 27)]. Boxes show the range between upper and lower
quartiles; horizontal lines within each data box show median value. Data points are shown
for outliers only. The difference in relative expression between the two groups was highly
significant (P 5 0.0001).
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in relatives of the index cases was 31.2 1 16.9 years, with a range of 1 to 71 years [21]. With
respect to the seven novel missense variants reported here, all had high average predicted
DDG values (range, 4.81 to 13.16 kcal/mol), and six were deeply buried within the protein,
strongly supporting pathogenicity. All these cases were also predicted as deleterious or
probably pathogenic by commonly used tools for in silico pathogenicity prediction; however,
the comparatively low specificity of all these tools for variants inMEN1 highlights the value
of thermodynamic analysis as a means of reducing false-positive calls.
As might be expected, our analysis showed that variants that are buried within the menin
structure are predicted to result in greatest structural destabilization. In fact, the majority
(86.3%) of reported germline pathogenic variants in MEN1 are buried, suggesting that any
novel variant that is solvent inaccessible (RSA, 0.2) and has a predicted DDG.4 kcal/mol is
also highly likely to be pathogenic. Nevertheless, a number of pathogenic variants lie on the
surface of menin, and many of these have relatively low DDG values. A number of these
variants lie at or close to positions of known interactions with binding partners, such as JunD,
KMT2A, or PSIP, where they presumably have an adverse effect on binding of these factors,
emphasizing the value of integrating all known structural annotations into a final classi-
fication of the likely effect of a variant.
Our data also suggest the possible existence of an as-yet unidentified interaction of menin,
as evidenced by the cluster of pathogenic variants lying on the protein surface opposite the
JunD binding pocket. Interestingly, in a recent analysis of the spatial distribution ofmissense
variants [52],MEN1 was identified as one of a group of genes displaying substantial spatial
clustering of pathogenic and likely pathogenic missense variants in the ClinVar database
[53], but not of benign or likely benignmissense variants reported in the gnomAD. Inspection
of ClinVar (accessed 19 September 2019) revealed that of 346 missense variants in MEN1,
only 50 unique variants (excluding start-loss variants) were classified as pathogenic or likely
pathogenic, with a large majority (276) classed as being of uncertain significance. Although
we used a different database, HGMD Pro, as the source for our data set of “pathogenic”
Figure 8. Use of thermodynamic analysis to assess the effect of novel missense variants. (a)
Receiver operating characteristic curves for groups of pathogenic and benign variants as
functions of DDG value [red line; area under the curve (AUC), 0.833], REVEL score (blue
line; AUC, 0.864), PolyPhen2 probability for pathogenicity (black line; AUC, 0.819), and SIFT
score (broken black line; AUC, 0.819). Open circles on DDG and REVEL traces indicate
positions corresponding to threshold values of 3 and 0.7 kcal/mol, respectively. (b) Scatter
plot of DDG value against REVEL score for all variants (red circles, pathogenic; blue fill,
benign; gray fill, uncertain; cyan fill, novel). Where different nucleotide substitutions gave
rise to the same amino acid change, the REVEL score was calculated as an average of values
for the individual nucleotide variants. Broken horizontal and vertical lines indicate
thresholds of DDG 5 3 kcal/mol and REVEL score 5 0.7, respectively. Note that all seven
novel missense variants are clustered in the upper right quadrant of the plot.
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variants, there is considerable overlap between the two, with 39 of 50 (78%) of the pathogenic
or likely pathogenic ClinVar variants also being present in our data set, whereas a further 27
variants in our data set were colocalized with a ClinVar variant. However, the discrepancy
between the total number of pathogenic variants in the two data sets highlights the need for
more reliable tools for classification of variants in MEN1.
In terms of the broader applicability of this approach, our work builds upon the reported
analysis of MSH2 and PAH variants and applies it to the classification of novel clinical
variants.Whether the same approach can be used for other proteins remains to be determined.
One obvious limitation of structural analysis is, by definition, the need for a suitable structural
model.However, evenwhenno experimental structures are available for a protein of interest, it
may still be possible to use comparative modeling to generate a reliable model of regions or
domains for structural analysis. Another likely limitation is the architecture of the protein
itself. Both menin and MSH2 are relatively compact, globular proteins, with low surface area/
volume ratio and a high proportion of amino acids in regions of secondary structure. As a result,
the effect of missense variants on the internal geometry and thermodynamic stability of the
proteins is amenable to in silico prediction, particularly given the availability of suitable high-
quality PDB structures. It seems likely, therefore, that the approach used here has broader
applicability in proteins that contain a high proportion of buried residues in regions of strong
secondary structure. Indeed, the potential for wider use of in silico thermodynamic analysis of
protein stability as part of a pipeline for assessing the effect of missense variants was recently
reviewed [54]. However, less well-structured proteins, or fibrillar proteins in which a greater
proportion of amino acids are exposed to solvent, are likely to be less amenable to such study, as
the confidence with which the structural and thermodynamic effects of missense variants can
be predicted will be greatly reduced. Such rules are likely to be revealed only by a proteome-
wide study, which is beyond the scope of this manuscript.
In summary, we have shown that structural analysis of missense substitutions in MEN1
can be used to identify variants that are likely to destabilize the protein and thus potentially
aid in variant classification. Given that all analyses described herein used publicly available
data and freely available software that did not require specialist bioinformatic skills or
infrastructure, such analysis lies within the capability of any genetics laboratory or testing
service. As such, there is significant scope for making greater use of protein structural data in
the routine interpretation of genetic variations.
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